Name (Synonyms) | Correlation | |
---|---|---|
drug3051 | Vehicle Control Wiki | 1.00 |
drug85 | APL-9 Wiki | 1.00 |
drug1688 | Matched placebo Wiki | 1.00 |
drug285 | Atorvastatin 20mg Wiki | 1.00 |
drug3307 | intermediate dose Enoxaparin/ unfractionated heparin Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.10 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.09 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
In a 2x2 factorial design randomized controlled trial, the investigators aim to elaborate the safety and efficacy of two pharmacological regimens on outcomes of critically-ill patients with COVID-19. The first randomization entails open-label assignment to intermediate versus standard dose prophylactic anticoagulation. The investigators hypothesize that intermediate dose compared with standard prophylactic dose anticoagulation will have a superior efficacy with respect to a composite of venous thromboembolism (VTE), requirement for extracorporeal membrane oxygenation (ECMO), or all-cause mortality. The second randomization will be double-blind assignment of the included patients to atorvastatin 20mg daily versus matching placebo. The hypothesis is that statin therapy, compared with placebo, will reduce the composite of VTE, need for ECMO, or all-cause mortality.
Description: Composite of objectively-confirmed venous thromboembolism, undergoing extracorporeal membrane oxygenation (ECMO), or death from any cause
Measure: Composite of incident VTE, undergoing ECMO, and all-cause mortality Time: 30 days from enrollment